Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway

Fig. 1

GK5 mediates gefitinib resistance. a Total Internal Reflection Fluorescence (TIRF) Microscopy images of exosomes isolated from plasma of EGFR TKI-sensitive and -resistant patients. b Exosomal GK5 mRNA in the plasma of gefitinib-sensitive and -resistant lung adenocarcinoma patients measured using TCLN biochips. c, d The RT-PCR and Western blotting on GK5 expression in gefitinib-sensitive PC9 and gefitinib-resistant PC9R cells. * p < 0.05 vs. the PC9 cells. e RT-PCR on GK5 expression in GK5-overexpressing (PC9-GK5) and control (PC9-Vector) PC9 cells. * p < 0.05 vs. control. f, g CCK8 assay and flow cytometry on viability and apoptosis of GK5-overexpressing and control PC9 cells. *P < 0.05 vs. control. h, i RT-PCR and Western blotting on GK5 expression in PC9R cells transfected with GK5-shRNA (shGK5–1 or − 2) or negative control shRNA (shNEG). j Morphology of PC9R cells expressing shGK5–1, − 2 or shNEG and cultured in the presence of 1 μM gefitinib. k CCK8 assay on the viability of PC9R cells expressing shGK5–1, − 2 or shNEG and treated with gefitinib. The data are representative of three experiments. * p < 0.05 vs. shNEG

Back to article page